Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $16.75.

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Friday.

Alto Neuroscience Trading Down 1.1 %

Shares of NYSE ANRO traded down $0.03 during mid-day trading on Friday, reaching $2.66. The company had a trading volume of 123,155 shares, compared to its average volume of 358,157. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The company has a 50-day moving average price of $3.67 and a two-hundred day moving average price of $6.22. Alto Neuroscience has a 1-year low of $2.60 and a 1-year high of $18.35.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. On average, research analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of hedge funds have recently modified their holdings of ANRO. Wells Fargo & Company MN lifted its position in shares of Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after acquiring an additional 3,139 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after acquiring an additional 3,715 shares during the period. Deutsche Bank AG lifted its position in shares of Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after acquiring an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $74,000. Finally, Jane Street Group LLC lifted its position in shares of Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after buying an additional 7,783 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.